Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TLC

Taiwan Liposome (TLC) Stock Price, News & Analysis

Taiwan Liposome logo

About Taiwan Liposome Stock (NASDAQ:TLC)

Advanced Chart

Key Stats

Today's Range
$7.00
$7.09
50-Day Range
$6.76
$7.63
52-Week Range
$4.07
$7.70
Volume
12,421 shs
Average Volume
133,095 shs
Market Capitalization
$294.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TLC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taiwan Liposome and its competitors with MarketBeat's FREE daily newsletter.

TLC Stock News Headlines

A $674B Industry Missed the Bigger Picture
TV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.
See More Headlines

TLC Stock Analysis - Frequently Asked Questions

Taiwan Liposome Company, Ltd. (NASDAQ:TLC) issued its earnings results on Wednesday, October, 28th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.06. The business had revenue of $2.28 million for the quarter, compared to the consensus estimate of $0.38 million. Taiwan Liposome had a negative trailing twelve-month return on equity of 120.45% and a negative net margin of 299.27%.

Taiwan Liposome (TLC) raised $29 million in an IPO on the week of November 19th 2018. The company issued 5,000,000 shares at $5.80 per share. Cantor acted as the underwriter for the IPO and CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw & Company (UK) Ltd. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Taiwan Liposome investors own include Avino Silver & Gold Mines (ASM), Trevena (TRVN), Bionano Genomics (BNGO), Pfizer (PFE), Wells Fargo & Company (WFC), Aadi Bioscience (AADI) and BioLineRx (BLRX).

Company Calendar

Last Earnings
10/28/2020
Today
7/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TLC
CIK
1722890
Fax
N/A
Employees
2,020
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$35.02 million
Net Margins
-299.27%
Pretax Margin
-306.10%
Return on Equity
-120.45%
Return on Assets
-55.11%

Debt

Debt-to-Equity Ratio
0.67
Current Ratio
3.01
Quick Ratio
3.01

Sales & Book Value

Annual Sales
$3.63 million
Price / Sales
81.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.83 per share
Price / Book
8.43

Miscellaneous

Outstanding Shares
42,077,000
Free Float
N/A
Market Cap
$294.54 million
Optionable
Not Optionable
Beta
0.99
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:TLC) was last updated on 7/31/2025 by MarketBeat.com Staff
From Our Partners